Barclays PLC Immunity Bio, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 361,036 shares of IBRX stock, worth $945,914. This represents 0.0% of its overall portfolio holdings.

Number of Shares

361,036

Previous 361,036 -0.0%

Holding current value

$945,914

Previous $1.34 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.32 - $6.7 $671,463 - $1.36 Million	202,248 Added 127.37%	361,036 $1.34 Million
Q2 2024 Aug 14, 2024	SELL	$4.82 - $9.15 $1.09 Million - $2.08 Million	-226,881 Reduced 58.83%	158,788 $1 Million
Q1 2024 May 15, 2024	SELL	$3.23 - $6.17 $303,219 - $579,214	-93,876 Reduced 19.58%	385,669 $2.07 Million
Q4 2023 Feb 15, 2024	BUY	$1.25 - $5.21 $543,965 - $2.27 Million	435,172 Added 980.71%	479,545 $2.41 Million
Q3 2023 Nov 07, 2023	SELL	$1.29 - $3.1 $20,763 - $49,897	-16,096 Reduced 26.62%	44,373 $75,000
Q2 2023 Aug 03, 2023	BUY	$1.53 - $6.41 $29,346 - $122,950	19,181 Added 46.46%	60,469 $168,000
Q1 2023 May 04, 2023	SELL	$1.35 - $4.78 $290,353 - $1.03 Million	-215,077 Reduced 83.89%	41,288 $75,000
Q4 2022 Feb 13, 2023	BUY	$4.35 - $6.77 $14,507 - $22,577	3,335 Added 1.32%	256,365 $1.3 Million
Q3 2022 Nov 03, 2022	BUY	$3.65 - $6.43 $883,909 - $1.56 Million	242,167 Added 2229.28%	253,030 $1.26 Million
Q2 2022 Aug 12, 2022	SELL	$2.68 - $6.14 $2,085 - $4,776	-778 Reduced 6.68%	10,863 $40,000
Q1 2022 May 16, 2022	BUY	$5.05 - $7.53 $58,787 - $87,656	11,641 New	11,641 $66,000

Others Institutions Holding IBRX

# of Institutions

204

Shares Held

70M

Call Options Held

1.68M

Put Options Held

1.31M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.05B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account